HEALTH PROFESSIONAL · SOURCE READING
Arsenic Trioxide With or Without Tretinoin
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Recurrent APL
For children with recurrent APL, the use of arsenic trioxide as a single agent or in regimens including tretinoin should be considered, depending on the therapy given during first remission. Arsenic trioxide is an active agent in adult patients with recurrent APL, with approximately 85% to 94% of patients achieving remission after treatment with this agent.[8-13] More limited data in children suggest that children with relapsed APL have a response to arsenic trioxide that is similar to that of adults.[8,10,13,14] Arsenic trioxide is well tolerated in children with relapsed APL, with a toxicity profile similar to that of adults.[8,13]
Arsenic trioxide is capable of inducing remissions in patients who relapse after having received arsenic trioxide with or without other agents during initial therapy.[13,15] However, APL cells may develop arsenic trioxide resistance when they acquire somatic variants in the PML domain of the PML::RARA fusion oncogene.[16]
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice
Triangle